Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$4.21
+2.7%
$3.62
$1.08
$5.00
$219.89M1.731.31 million shs189,324 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$13.57
+4.0%
$12.76
$9.40
$15.98
$549.59M0.75140,971 shs35,453 shs
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$24.98
+3.1%
$24.58
$3.18
$25.00
$2.37B2.472.28 million shs9.12 million shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-0.24%-4.87%+2.50%+8.47%+51.85%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
-1.88%-1.21%+7.94%+18.74%-17.87%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00%0.00%0.00%0.00%+2.71%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
3.5793 of 5 stars
3.32.00.03.82.90.80.6
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
4.3841 of 5 stars
2.04.02.51.13.13.32.5
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
2.50
Moderate Buy$9.33121.69% Upside
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.00
Hold$15.3312.99% Upside
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest PRVB, PAHC, ZIOP, and GTHX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
2/28/2024
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$4.00 ➝ $5.00
2/28/2024
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
2/13/2024
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$5.00 ➝ $4.00
2/13/2024
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $12.00
1/24/2024
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
$82.51M2.66N/AN/A$0.68 per share6.19
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$977.90M0.56$2.11 per share6.43$6.97 per share1.95
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$12.90M183.54N/AN/A$1.40 per share17.84
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-$47.97M-$0.95N/AN/AN/A-58.13%-106.04%-33.99%5/1/2024 (Confirmed)
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$32.61M$0.3637.6911.214.921.51%16.67%4.73%5/8/2024 (Confirmed)
Provention Bio, Inc. stock logo
PRVB
Provention Bio
-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest PRVB, PAHC, ZIOP, and GTHX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.29N/A-$0.29N/AN/AN/A  
5/1/2024N/A
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-$0.19N/A+$0.19N/AN/AN/A  
2/28/202412/31/2023
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million    
2/7/2024Q2 2024
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.27$0.33+$0.06$0.63$242.91 million$249.90 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.483.54%N/A133.33%N/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Latest PRVB, PAHC, ZIOP, and GTHX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2024
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Quarterly$0.124.5%3/5/20243/6/20243/27/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
1.46
3.87
3.45
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.66
3.12
1.60
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.19
1.93
1.92
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
24.21%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
37.39%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Insider Ownership

CompanyInsider Ownership
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
8.23%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
50.06%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
13.10%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
5.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
G1 Therapeutics, Inc. stock logo
GTHX
G1 Therapeutics
10052.23 million47.94 millionOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,92040.50 million20.23 millionOptionable
Provention Bio, Inc. stock logo
PRVB
Provention Bio
8294.78 million82.37 millionNot Optionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

PRVB, PAHC, ZIOP, and GTHX Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

G1 Therapeutics logo

G1 Therapeutics

NASDAQ:GTHX
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Phibro Animal Health logo

Phibro Animal Health

NASDAQ:PAHC
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Provention Bio logo

Provention Bio

NASDAQ:PRVB
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.